Brand Name

Xarelto

Generic Name
Rivaroxaban
View Brand Information
FDA approval date: July 01, 2011
Classification: Factor Xa Inhibitor
Form: Tablet, Kit, Granule, For

What is Xarelto (Rivaroxaban)?

XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)
Who is this study for: Patients with intracranial vascular atherostenosis
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug, Other
Study Drugs: Ticagrelor, Aspirin, Rivaroxaban, Clopidogrel
Study Phase: Phase 3

Summary: The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.

PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism
PEERLESS II: RCT of FlowTriever vs. Anticoagulation Alone in Pulmonary Embolism
Enrollment Status: Recruiting
Publish Date: December 12, 2025
Intervention Type: Drug, Device
Study Phase: Not Applicable

Summary: This study is a prospective, multicenter, randomized controlled trial of the FlowTriever System plus anticoagulation compared to anticoagulation alone for intermediate-risk acute PE.

Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study
Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study
Enrollment Status: Recruiting
Publish Date: December 08, 2025
Intervention Type: Drug
Study Phase: Not Applicable

Summary: This study investigates the efficacy and safety of direct oral anticoagulants (DOACs) in comparison with standard low-molecular-weight heparin (LMWH) for the prevention of venous thromboembolism in patients with hematological malignancies. Eligible participants will be randomized to receive reduced-dose apixaban, reduced-dose rivaroxaban, or standard-dose LMWH. The primary objective is to evaluate...

View All Clinical Trials

Related Latest Advances

Role of rivaroxaban in arteriovenous graft thrombosis after endovascular treatment and establishment and evaluation of a nomogram predictive model for postoperative recurrent thrombosis risk.
Role of rivaroxaban in arteriovenous graft thrombosis after endovascular treatment and establishment and evaluation of a nomogram predictive model for postoperative recurrent thrombosis risk.
Journal: Science progress
Published: December 16, 2025
Laboratory Testing of Direct Oral Anticoagulants.
Laboratory Testing of Direct Oral Anticoagulants.
Journal: Handbook of experimental pharmacology
Published: December 15, 2025
Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial.
Is there a role for anticoagulation with dabigatran in S. aureus bacteremia? Protocol for the adjunctive treatment domain of the Staphylococcus aureus Network Adaptive Platform (SNAP) randomised controlled trial.
Journal: BMJ open
Published: December 12, 2025
View All Latest Advances

Brand Information

XARELTO (rivaroxaban)
1DOSAGE FORMS AND STRENGTHS
  • 2.5 mg tablets: Round, light yellow, and film-coated with a triangle pointing down above a "2.5" marked on one side and "Xa" on the other side
  • 10 mg tablets: Round, light red, biconvex and film-coated with a triangle pointing down above a "10" marked on one side and "Xa" on the other side
  • 15 mg tablets: Round, red, biconvex, and film-coated with a triangle pointing down above a "15" marked on one side and "Xa" on the other side
  • 20 mg tablets: Triangle-shaped, dark red, and film-coated with a triangle pointing down above a "20" marked on one side and "Xa" on the other side
  • For oral suspension: white to off-white granules; once reconstituted, provide flavored white to off-white opaque liquid with a concentration of 1 mg/mL.
2CONTRAINDICATIONS
XARELTO is contraindicated in patients with:
  • active pathological bleeding
  • severe hypersensitivity reaction to XARELTO (e.g., anaphylactic reactions)
3ADVERSE REACTIONS
The following clinically significant adverse reactions are also discussed in other sections of the labeling:
  • Increased Risk of Stroke After Discontinuation in Nonvalvular Atrial Fibrillation
  • Bleeding Risk
  • Spinal/Epidural Hematoma
3.1Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
During clinical development for the approved indications, 34,947 adult patients were exposed to XARELTO.
3.2Postmarketing Experience
The following adverse reactions have been identified during post-approval use of XARELTO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
Blood and lymphatic system disorders:agranulocytosis, thrombocytopenia
Hepatobiliary disorders:jaundice, cholestasis, hepatitis (including hepatocellular injury)
Immune system disorders:hypersensitivity, anaphylactic reaction, anaphylactic shock, angioedema
Nervous system disorders:hemiparesis
Renal disorders:Anticoagulant-related nephropathy
Respiratory, thoracic and mediastinal disorders:Eosinophilic pneumonia
Skin and subcutaneous tissue disorders:Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS)
Injury, poisoning and procedural complications:Atraumatic splenic rupture
4OVERDOSAGE
Overdose of XARELTO may lead to hemorrhage. Discontinue XARELTO and initiate appropriate therapy if bleeding complications associated with overdosage occur. Rivaroxaban systemic exposure is not further increased at single doses >50 mg due to limited absorption. The use of activated charcoal to reduce absorption in case of XARELTO overdose may be considered. Due to the high plasma protein binding, rivaroxaban is not dialyzable
5DESCRIPTION
Rivaroxaban, a factor Xa (FXa) inhibitor, is the active ingredient in XARELTO
Chemical Structure
Rivaroxaban is a pure (
Each XARELTO tablet contains 2.5 mg, 10 mg, 15 mg, or 20 mg of rivaroxaban. The inactive ingredients of XARELTO are: croscarmellose sodium, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. Additionally, the proprietary film coating mixture used for XARELTO 2.5 mg is Opadry
XARELTO for oral suspension is supplied as granules in bottles containing 155 mg of rivaroxaban (1 mg of rivaroxaban per mL after reconstitution). The inactive ingredients are: anhydrous citric acid, hypromellose, mannitol, microcrystalline cellulose and carboxymethylcellulose sodium, sodium benzoate, sucralose, sweet and creamy flavor and xanthan gum.
6HOW SUPPLIED/STORAGE AND HANDLING
XARELTO
  • 2.5 mg tablets are round, light yellow, and film-coated with a triangle pointing down above a "2.5" marked on one side and "Xa" on the other side. The tablets are supplied in the packages listed:
  • 10 mg tablets are round, light red, biconvex film-coated tablets marked with a triangle pointing down above a "10" on one side, and "Xa" on the other side. The tablets are supplied in the packages listed:
  • 15 mg tablets are round, red, biconvex film-coated tablets with a triangle pointing down above a "15" marked on one side and "Xa" on the other side. The tablets are supplied in the packages listed:
  • 20 mg tablets are triangle-shaped, dark red film-coated tablets with a triangle pointing down above a "20" marked on one side and "Xa" on the other side. The tablets are supplied in the packages listed:
  • Starter Pack for treatment of deep vein thrombosis and treatment of pulmonary embolism:
XARELTO
7PATIENT COUNSELING INFORMATION
For the tablets, advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide).
For the suspension, advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).
8Instructions for Use XARELTO ® (zah-REL-toe) (rivaroxaban) for oral suspension
Image
This Instructions for Use contains information on how to give a dose of XARELTO oral suspension.
Read this Instructions for Use before giving XARELTO and each time you get a refill. There may be new information. This leaflet does not take the place of talking with your doctor about your child's medical condition or treatment.
Important information:
  • XARELTO suspension is for oral use only.
  • Give XARELTO to your child exactly as prescribed by your doctor. The adult caregiver should give the dose. If you have questions, contact your doctor or pharmacist for more information on giving a dose.
  • Only use the oral dosing syringe provided with XARELTO oral suspension.Contact your doctor or pharmacist if the oral dosing syringe is missing, lost or damaged.
ImageStorage information
Store XARELTO oral suspension at room temperature between
Store the bottle upright with the oral dosing syringes in the original carton.
Keep XARELTO and all medicines out of reach of children.
XARELTO Oral Dosing Syringe:
XARELTO Bottle
Image
Image
Check "Discard after" date on the XARELTO bottle.
If "Discard after" date has passed,
Image
Wash hands.
Wash your hands well with soap and warm water.
Image
Shake bottle slowly for 10 seconds before each use.
Image
Check XARELTO oral suspension.
If there are lumps or granules at the bottom of the bottle, shake the bottle
Find your dose line.
You can use either side of the syringe to set your dose.
If using mL side of syringe:
Top of the plunger should line up with the prescribed mL.
If using color side of syringe:
Top of the plunger should line up with the prescribed mL dose line at the
Image
If your dose is more than 5 mL.
You will need to use the same syringe more than one time. Repeat Steps 4 and 5 to complete your dose. Ask your pharmacist if you are not sure.
Image
Image
Push plunger all the way in to remove air.
Image
Insert oral dosing syringe into bottle adaptor.
Twist off the cap from the bottle.
Do notremove the bottle adaptor from the bottle.
Insert the syringe tip into the bottle adaptor.
Image
Fill oral dosing syringe.
Turn the bottle upside down, as shown.
Pull the plunger to fill the oral dosing syringe
ImageCAUTION:
Make sure you have enough medicine for a full dose. Do not take a partial dose.
Image
Tap syringe to move air bubbles to the top.
Doing this helps set the correct dose.
Image
Adjust to your prescribed dose.
If using mL side of syringe:Push plunger to align with the prescribed dose line.
If using color side of syringe:Push plunger to align with the prescribed mL dose line at the bottom of the color band.
Image
Remove oral dosing syringe.
Place the bottle on a flat surface.
Remove the oral dosing syringe from the bottle.
Image
Give the dose.
Place the oral dosing syringe gently into the child's mouth with
This allows the child to swallow naturally.
Make sure the child swallows the full dose.
If your child vomits or spits out the medicine repeatedly, contact your child's doctor right away.
Image
Close XARELTO bottle and rinse oral dosing syringe.
Rinse the oral dosing syringe with tap water and let it air dry.
Disposing XARELTO bottle and syringe
  • Throw the XARELTO bottle away in your household trash.
  • Throw away any used oral dosing syringe with the opening of a new XARELTO bottle.
  • Do not pour XARELTO suspension down the drain(for example: sink, toilet, shower or tub).
  • Do notrecycle the bottle.
Manufactured for:
For patent information: www.janssenpatents.com
© 2021 Janssen Pharmaceutical Companies
This Instructions for Use has been approved by the U.S. Food and Drug Administration.